Novartis sets the tone for the radiopharma push with a prized acquisition winning breakthrough therapy designation
The crown jewel of a multibillion-dollar Novartis acquisition has won a new endorsement from the FDA, and it’s a program at the forefront of the industry’s radiopharma push.
Regulators granted Lu-PSMA-617 breakthrough therapy designation Wednesday, Novartis announced, roughly three months after the candidate read out positive Phase III results in metastatic castration-resistant prostate cancer. The move marks not only a win for Novartis but for the up-and-coming radiopharmaceuticals field, which has attracted heavy interest in the last couple years.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.